Amphastar Pharmaceuticals Company Profile (NASDAQ:AMPH)

About Amphastar Pharmaceuticals (NASDAQ:AMPH)

Amphastar Pharmaceuticals logoAmphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AMPH
  • CUSIP: N/A
  • Web: www.amphastar.com
Capitalization:
  • Market Cap: $708.92 million
  • Outstanding Shares: 45,737,000
Average Prices:
  • 50 Day Moving Avg: $15.04
  • 200 Day Moving Avg: $16.75
  • 52 Week Range: $12.05 - $21.75
P/E:
  • Trailing P/E Ratio: 81.63
  • Foreward P/E Ratio: 19.62
  • P/E Growth: 1.73
Sales & Book Value:
  • Annual Revenue: $252.47 million
  • Price / Sales: 2.81
  • Book Value: $7.08 per share
  • Price / Book: 2.19
Profitability:
  • EBIDTA: $25.34 million
  • Net Margins: 7.75%
  • Return on Equity: 6.79%
  • Return on Assets: 5.14%
Debt:
  • Debt-to-Equity Ratio: 0.10%
  • Current Ratio: 3.13%
  • Quick Ratio: 1.64%
Misc:
  • Average Volume: 331,116 shs.
  • Beta: 1.74
  • Short Ratio: 5.3
 

Frequently Asked Questions for Amphastar Pharmaceuticals (NASDAQ:AMPH)

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) posted its quarterly earnings results on Monday, May, 8th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by $0.03. The firm had revenue of $56.67 million for the quarter, compared to analyst estimates of $63.74 million. Amphastar Pharmaceuticals had a return on equity of 6.79% and a net margin of 7.75%. The firm's quarterly revenue was down 4.5% compared to the same quarter last year. During the same period last year, the company posted $0.12 earnings per share. View Amphastar Pharmaceuticals' Earnings History.

Where is Amphastar Pharmaceuticals' stock going? Where will Amphastar Pharmaceuticals' stock price be in 2017?

6 brokerages have issued 12 month price targets for Amphastar Pharmaceuticals' shares. Their forecasts range from $16.00 to $29.00. On average, they anticipate Amphastar Pharmaceuticals' stock price to reach $20.17 in the next twelve months. View Analyst Ratings for Amphastar Pharmaceuticals.

What are analysts saying about Amphastar Pharmaceuticals stock?

Here are some recent quotes from research analysts about Amphastar Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California. " (5/16/2017)
  • 2. Piper Jaffray Companies analysts commented, "Amphastar reported 4Q16 diluted EPS of $0.01 on revenues of $63.5M, compared to Street estimates of ($0.01) and $55.9M, respectively. Though the base business is facing some challenges as we move further into 2017 (i.e., uncertainty over the trajectory of generic enoxaparin; the potential removal of AMPH's injectable epinephrine given that it is an unapproved product), we nonetheless remain bullish on AMPH shares, given that the pipeline continues to advance and given our view that it very much has the potential to drive transformative longer-term cash generation (AMPH also being one of the few generics companies solely focused on more complex dosage forms also doesn't hurt). We reiterate our Overweight rating and are lowering our PT to $20 from $22 (see below for more details)." (3/14/2017)
  • 3. BMO Capital Markets analysts commented, " AMPH reported 4Q16 revenue of $63.5mm vs. BMO/consensus $56.5mm/ $55.9mm and adj. EPS of $0.01 vs. BMO/consensus $0.02/($0.01). Revenue upside was offset by lower gross margin and higher R&D. Without 2017 revenue/EPS guidance, there is some uncertainty with the numbers given a number of moving parts, including Enoxaparin sales, potential withdrawal of Epinephrine vials, overall pricing pressure, contribution from new approvals, and higher spending levels to invest in the pipeline. We are lowering estimates and our target goes to $16 from $18. The pipeline has value, but we await near-term execution." (3/14/2017)
  • 4. Needham & Company LLC analysts commented, "While AMPH reported 4Q16 results that bested the Street's expectations on both top and bottom lines, the company has taken its lumps from the FDA over the last three months. Two recent CRLs (Primatene Mist and intranasal naloxone) have delayed two branded product opportunities by at least 12 months. FDA recently requested that AMPH discontinue the distribution of its epinephrine vial product, which generated $18.6MM in 2016 revenues. The last shot on goal in terms of potential near-term approvals is an ANDA product (undisclosed injectable), which AMPH mgmt expects will make meaningful sales contributions in 2017. The ANDA product pipeline is expected to make additional contributions in 2018. We maintain our Buy rating and adjust our PT to $18 (from $20) to account for a reduction in base business revenues." (3/14/2017)

Who are some of Amphastar Pharmaceuticals' key competitors?

Who owns Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), State Street Corp (2.31%), Dimensional Fund Advisors LP (0.00%), Rothschild Asset Management Inc. (0.00%), Acadian Asset Management LLC (1.24%) and Teachers Advisors LLC (0.00%). Company insiders that own Amphastar Pharmaceuticals stock include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters. View Institutional Ownership Trends for Amphastar Pharmaceuticals.

Who sold Amphastar Pharmaceuticals stock? Who is selling Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Acadian Asset Management LLC, Prudential Financial Inc., Alliancebernstein L.P., Russell Investments Group Ltd., Kalmar Investments Inc. DE, Goldman Sachs Group Inc. and PNC Financial Services Group Inc.. Company insiders that have sold Amphastar Pharmaceuticals stock in the last year include Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Rong Zhou, Stephen B Shohet and William J Peters. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Who bought Amphastar Pharmaceuticals stock? Who is buying Amphastar Pharmaceuticals stock?

Amphastar Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Rothschild Asset Management Inc., Citadel Advisors LLC, Dimensional Fund Advisors LP, State Street Corp, Sei Investments Co., Nordea Investment Management AB, Cornerstone Capital Management Holdings LLC. and Bank of New York Mellon Corp. View Insider Buying and Selling for Amphastar Pharmaceuticals.

How do I buy Amphastar Pharmaceuticals stock?

Shares of Amphastar Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Amphastar Pharmaceuticals stock cost?

One share of Amphastar Pharmaceuticals stock can currently be purchased for approximately $15.50.

Analyst Ratings

Consensus Ratings for Amphastar Pharmaceuticals (NASDAQ:AMPH) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $20.17 (30.11% upside)

Analysts' Ratings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017Jefferies Group LLCLower Price TargetBuy$21.00 -> $20.00MediumView Rating Details
3/14/2017Raymond James Financial, Inc.DowngradeStrong-Buy -> Outperform$21.00 -> $18.00HighView Rating Details
3/14/2017Piper Jaffray CompaniesLower Price TargetOverweight$22.00 -> $20.00HighView Rating Details
3/14/2017BMO Capital MarketsLower Price TargetMarket Perform$18.00 -> $16.00HighView Rating Details
3/14/2017Needham & Company LLCLower Price TargetBuy$20.00 -> $18.00HighView Rating Details
12/21/2016Wells Fargo & CoReiterated RatingOutperform$22.00 -> $29.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Earnings by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Earnings History by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017$0.06$0.03$63.74 million$56.67 millionViewListenView Earnings Details
3/13/2017Q4 2016($0.01)$0.01$55.78 million$63.54 millionViewN/AView Earnings Details
11/8/2016Q3$0.03$0.14$65.12 million$64.20 millionViewListenView Earnings Details
8/8/2016Q2$0.01$0.23$62.10 million$68.00 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)$0.12$62.00 million$59.40 millionViewN/AView Earnings Details
3/14/2016Q415($0.04)$0.19$64.48 million$76.90 millionViewN/AView Earnings Details
11/12/2015Q315($0.20)($0.01)$19.49 million$63.90 millionViewListenView Earnings Details
8/12/2015Q215($0.11)($0.09)$19.49 million$53.85 millionViewListenView Earnings Details
5/13/2015Q115($0.17)($0.01)$45.87 million$56.89 millionViewListenView Earnings Details
3/24/2015Q414($0.06)($0.03)$54.90 million$55.90 millionViewN/AView Earnings Details
11/12/2014Q314($0.11)($0.11)$45.89 million$59.70 millionViewN/AView Earnings Details
8/12/2014Q2 2014($0.11)$0.02$44.23 million$49.00 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)
2017 EPS Consensus Estimate: $0.41
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.09$0.09$0.09
Q2 20171$0.04$0.04$0.04
Q3 20171$0.10$0.10$0.10
Q4 20171$0.18$0.18$0.18
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Insider Ownership Percentage: 29.30%
Institutional Ownership Percentage: 49.09%
Insider Trades by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Insider Trades by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/11/2017Richard K PrinsDirectorSell7,500$15.43$115,725.00View SEC Filing  
1/3/2017Floyd F PetersenDirectorSell400$18.61$7,444.00View SEC Filing  
12/15/2016Diane G GerstEVPSell2,940$20.51$60,299.40View SEC Filing  
12/5/2016Rong ZhouEVPSell61$20.70$1,262.70View SEC Filing  
12/1/2016Floyd F PetersenDirectorSell400$20.26$8,104.00View SEC Filing  
11/28/2016Jason B ShandellInsiderSell26,335$20.48$539,340.80View SEC Filing  
11/15/2016Howard LeeDirectorSell37,994$20.65$784,576.10View SEC Filing  
10/3/2016Floyd F PetersenDirectorSell400$18.75$7,500.00View SEC Filing  
9/26/2016Jason B ShandellInsiderSell56,996$19.50$1,111,422.00View SEC Filing  
9/20/2016Jack Y ZhangCEOSell444,199$21.03$9,341,504.97View SEC Filing  
9/8/2016Floyd F PetersenDirectorSell3,000$19.05$57,150.00View SEC Filing  
9/1/2016Howard LeeDirectorSell10,381$18.78$194,955.18View SEC Filing  
8/22/2016Jason B ShandellGeneral CounselSell10,000$19.95$199,500.00View SEC Filing  
8/19/2016Diane G GerstEVPSell24,046$19.28$463,606.88View SEC Filing  
8/18/2016Richard K PrinsDirectorSell3,086$19.62$60,547.32View SEC Filing  
8/17/2016Jason B ShandellInsiderSell5,987$18.86$112,914.82View SEC Filing  
8/16/2016Stephen B ShohetDirectorSell48,375$18.24$882,360.00View SEC Filing  
8/15/2016Michael A ZasloffDirectorSell48,375$18.15$878,006.25View SEC Filing  
8/12/2016William J PetersCFOSell1,027$18.19$18,681.13View SEC Filing  
8/11/2016Jason B ShandellPresidentSell5,636$18.01$101,504.36View SEC Filing  
8/11/2016Richard K PrinsDirectorSell13,993$18.03$252,293.79View SEC Filing  
7/18/2016William J PetersCFOSell2,297$17.76$40,794.72View SEC Filing  
6/15/2016Rong ZhouEVPSell1,551$15.85$24,583.35View SEC Filing  
6/13/2016Richard K PrinsDirectorSell7,500$15.94$119,550.00View SEC Filing  
6/9/2016Jason B ShandellPresidentSell9,904$16.43$162,722.72View SEC Filing  
6/2/2016William J PetersCFOSell2,297$16.00$36,752.00View SEC Filing  
5/25/2016Jason B ShandellPresidentSell1,074$15.60$16,754.40View SEC Filing  
5/18/2016Diane G GerstEVPSell1,427$13.97$19,935.19View SEC Filing  
5/17/2016Richard K PrinsDirectorSell3,200$13.56$43,392.00View SEC Filing  
4/19/2016Diane G GerstEVPSell21,244$12.89$273,835.16View SEC Filing  
4/18/2016Diane G GerstEVPSell15,637$12.83$200,622.71View SEC Filing  
3/17/2016Richard K PrinsDirectorSell2,400$11.25$27,000.00View SEC Filing  
12/17/2015Stephen B. ShohetDirectorSell30,770$14.19$436,626.30View SEC Filing  
12/16/2015Howard LeeDirectorSell38,462$14.34$551,545.08View SEC Filing  
12/16/2015Rong ZhouEVPSell772$14.29$11,031.88View SEC Filing  
12/11/2015Jack Y ZhangCEOSell63,300$14.25$902,025.00View SEC Filing  
12/8/2015Jack Y ZhangCEOSell68,117$14.71$1,002,001.07View SEC Filing  
12/3/2015Jack Y ZhangCEOSell38,583$15.45$596,107.35View SEC Filing  
8/18/2015Richard K PrinsDirectorSell9,100$14.66$133,406.00View SEC Filing  
8/17/2015Richard K. PrinsDirectorSell5,400$14.70$79,380.00View SEC Filing  
7/17/2015Michael A ZasloffDirectorSell7,692$17.41$133,917.72View SEC Filing  
6/17/2015Rong ZhouEVPSell1,000$16.48$16,480.00View SEC Filing  
6/15/2015Jack Y ZhangCEOSell45,382$16.29$739,272.78View SEC Filing  
6/12/2015Jack Y ZhangCEOSell160,495$16.23$2,604,833.85View SEC Filing  
6/9/2015Jack Y ZhangCEOSell193,758$16.43$3,183,443.94View SEC Filing  
5/22/2015Richard K PrinsDirectorSell29,452$14.77$435,006.04View SEC Filing  
5/19/2015Richard K PrinsDirectorSell3,000$14.94$44,820.00View SEC Filing  
4/9/2015Marilyn J PurchaseVPSell28,000$15.79$442,120.00View SEC Filing  
4/8/2015Diane G GerstSVPSell10,000$15.79$157,900.00View SEC Filing  
8/25/2014Howard LeeDirectorBuy6,000$10.84$65,040.00View SEC Filing  
8/19/2014Michael A ZasloffDirectorBuy3,500$10.00$35,000.00View SEC Filing  
8/18/2014Richard K PrinsDirectorBuy4,000$10.02$40,080.00View SEC Filing  
8/15/2014Floyd F PetersenDirectorBuy3,200$10.35$33,120.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Latest Headlines for Amphastar Pharmaceuticals (NASDAQ:AMPH)
Source:
DateHeadline
seekingalpha.com logoMannKind Contract With Amphastar
seekingalpha.com - May 24 at 3:31 PM
americanbankingnews.com logoAmphastar Pharmaceuticals Inc (AMPH) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - May 16 at 9:32 PM
finance.yahoo.com logoEdited Transcript of AMPH earnings conference call or presentation 8-May-17 9:00pm GMT
finance.yahoo.com - May 13 at 2:10 AM
americanbankingnews.com logoAmphastar Pharmaceuticals Inc (AMPH) Director Sells $115,725.00 in Stock
www.americanbankingnews.com - May 12 at 8:01 PM
americanbankingnews.com logoAmphastar Pharmaceuticals Inc (AMPH) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 12 at 6:43 PM
americanbankingnews.com logoJefferies Group Brokers Decrease Earnings Estimates for Amphastar Pharmaceuticals Inc (AMPH)
www.americanbankingnews.com - May 11 at 9:24 AM
nasdaq.com logoAmphastar Pharmaceuticals to Present at the 20th Annual Bank of America Merrill Lynch Health Care Conference - Nasdaq
www.nasdaq.com - May 10 at 8:40 PM
americanbankingnews.com logoAmphastar Pharmaceuticals' (AMPH) Buy Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - May 10 at 9:59 AM
finance.yahoo.com logoAmphastar Pharmaceuticals to Present at the 20th Annual Bank of America Merrill Lynch Health Care Conference
finance.yahoo.com - May 10 at 9:22 AM
americanbankingnews.com logoAmphastar Pharmaceuticals Inc (AMPH) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - May 9 at 10:22 AM
globenewswire.com logoAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2017 - GlobeNewswire (press release)
globenewswire.com - May 9 at 9:00 AM
finance.yahoo.com logoAmphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2017
finance.yahoo.com - May 8 at 8:43 PM
marketbeat.com logoAmphastar beats 1Q profit forecasts
marketbeat.com - May 8 at 5:55 PM
finance.yahoo.com logoInvestor Network: Amphastar Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 3:27 PM
americanbankingnews.com logoAmphastar Pharmaceuticals Inc (AMPH) Expected to Post Quarterly Sales of $65.27 Million
www.americanbankingnews.com - May 6 at 7:54 AM
americanbankingnews.com logoAmphastar Pharmaceuticals Inc (AMPH) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - May 5 at 9:14 PM
americanbankingnews.com logoZacks: Analysts Expect Amphastar Pharmaceuticals Inc (AMPH) to Announce $0.06 EPS
www.americanbankingnews.com - May 4 at 10:50 PM
nasdaq.com logoAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2017 - Nasdaq
www.nasdaq.com - May 4 at 3:35 PM
finance.yahoo.com logoAmphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on May 8, 2017
finance.yahoo.com - May 4 at 3:35 PM
finance.yahoo.com logoAmphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2017
finance.yahoo.com - May 4 at 3:35 PM
americanbankingnews.com logoAmphastar Pharmaceuticals (AMPH) Given Coverage Optimism Rating of 0.34
www.americanbankingnews.com - May 2 at 9:24 AM
americanbankingnews.com logoAmphastar Pharmaceuticals (AMPH) Getting Favorable Press Coverage, Analysis Shows
www.americanbankingnews.com - April 29 at 9:55 AM
finance.yahoo.com logoAmphastar Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AMPH) : April 26, 2017
finance.yahoo.com - April 26 at 8:43 PM
americanbankingnews.com logoAmphastar Pharmaceuticals (AMPH) Receives Coverage Optimism Rating of 0.15
www.americanbankingnews.com - April 26 at 3:16 PM
finance.yahoo.com logoAmphastar Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AMPH-US : April 25, 2017
finance.yahoo.com - April 25 at 9:12 AM
americanbankingnews.com logoAmphastar Pharmaceuticals (AMPH) Given Daily Coverage Optimism Score of 0.08
www.americanbankingnews.com - April 23 at 8:20 AM
americanbankingnews.com logoAmphastar Pharmaceuticals Inc (AMPH) Given a $21.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - April 21 at 4:20 PM
americanbankingnews.com logoAmphastar Pharmaceuticals (AMPH) Earning Somewhat Positive News Coverage, Report Finds
www.americanbankingnews.com - April 20 at 8:21 AM
prnewswire.com logoResearch Reports Initiation on Healthcare Stocks -- Valeant Pharma, Delcath Systems, Alkermes, and - PR Newswire (press release)
www.prnewswire.com - April 18 at 7:49 AM
americanbankingnews.com logoAmphastar Pharmaceuticals Inc (AMPH) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 17 at 6:37 PM
americanbankingnews.com logoAmphastar Pharmaceuticals (AMPH) Getting Somewhat Favorable Press Coverage, Study Finds
www.americanbankingnews.com - April 17 at 11:59 AM
americanbankingnews.com logo$65.27 Million in Sales Expected for Amphastar Pharmaceuticals Inc (AMPH) This Quarter
www.americanbankingnews.com - April 15 at 7:58 AM
americanbankingnews.com logoSomewhat Positive Media Coverage Unlikely to Effect Amphastar Pharmaceuticals (AMPH) Share Price
www.americanbankingnews.com - April 14 at 4:34 PM
americanbankingnews.com logoZacks: Brokerages Expect Amphastar Pharmaceuticals Inc (AMPH) to Post $0.06 EPS
www.americanbankingnews.com - April 13 at 8:28 PM
americanbankingnews.com logoShort Interest in Amphastar Pharmaceuticals Inc (AMPH) Rises By 10.5%
www.americanbankingnews.com - April 13 at 7:24 AM
globenewswire.com logoAmphastar Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - April 2 at 9:43 AM
finance.yahoo.com logoAmphastar Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 31 at 3:39 PM
finance.yahoo.com logoBlog Coverage Sonoma Pharmaceuticals Announced FDA Clearance for Loyon Skin Descaler
finance.yahoo.com - March 30 at 3:55 PM
americanbankingnews.com logoAmphastar Pharmaceuticals Inc (AMPH) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 22 at 12:02 PM
finance.yahoo.com logoAMPHASTAR PHARMACEUTICALS, INC. Financials
finance.yahoo.com - March 18 at 3:26 PM
americanbankingnews.com logoAmphastar Pharmaceuticals Inc (AMPH) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - March 17 at 9:06 PM
seekingalpha.com logoThese Stocks Are Aiming For The Billion-Dollar Opioid Addiction Market
seekingalpha.com - March 17 at 3:02 AM
biz.yahoo.com logoAMPHASTAR PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 15 at 3:41 PM
finance.yahoo.com logoEdited Transcript of AMPH earnings conference call or presentation 13-Mar-17 9:00pm GMT
finance.yahoo.com - March 15 at 3:41 PM
americanbankingnews.com logoAmphastar Pharmaceuticals Inc (AMPH) PT Lowered to $20.00
www.americanbankingnews.com - March 14 at 9:27 PM
finance.yahoo.com logoAmphastar Pharmaceuticals downgraded by Raymond James
finance.yahoo.com - March 14 at 8:29 PM
reuters.com logoBRIEF-Amphastar Pharma Q4 gaap loss per share $0.06 - Reuters
www.reuters.com - March 14 at 8:00 AM
seekingalpha.com logoAmphastar Pharmaceuticals (AMPH) Q4 2016 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 14 at 8:00 AM
us.rd.yahoo.com logoAmphastar Pharmaceuticals Reports Financial Results for the Three Months and Fiscal Year Ended December 31, 2016
us.rd.yahoo.com - March 13 at 8:36 PM
us.rd.yahoo.com logo4:25 pm Amphastar Pharmaceuticals misses by $0.03, beats on revs
us.rd.yahoo.com - March 13 at 8:36 PM

Social

Chart

Amphastar Pharmaceuticals (AMPH) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff